GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Assertio Holdings Inc (FRA:DPOA) » Definitions » Total Liabilities

Assertio Holdings (FRA:DPOA) Total Liabilities : €135.7 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Assertio Holdings Total Liabilities?

Assertio Holdings's Total Liabilities for the quarter that ended in Mar. 2024 was €135.7 Mil.

Assertio Holdings's quarterly Total Liabilities declined from Sep. 2023 (€175.36 Mil) to Dec. 2023 (€136.10 Mil) and declined from Dec. 2023 (€136.10 Mil) to Mar. 2024 (€135.67 Mil).

Assertio Holdings's annual Total Liabilities declined from Dec. 2021 (€198.36 Mil) to Dec. 2022 (€177.65 Mil) and declined from Dec. 2022 (€177.65 Mil) to Dec. 2023 (€136.10 Mil).


Assertio Holdings Total Liabilities Historical Data

The historical data trend for Assertio Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assertio Holdings Total Liabilities Chart

Assertio Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 422.29 203.66 198.36 177.65 136.10

Assertio Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 152.81 139.29 175.36 136.10 135.67

Assertio Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Assertio Holdings's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=85.687+(36.383+8.74
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+5.287+0)
=136.1

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=262.646-126.549
=136.1

Assertio Holdings's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=85.048+(36.49+8.77
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+5.365+0)
=135.7

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=259.408-123.734
=135.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Assertio Holdings Total Liabilities Related Terms

Thank you for viewing the detailed overview of Assertio Holdings's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Assertio Holdings (FRA:DPOA) Business Description

Traded in Other Exchanges
Address
100 South Saunders Road, Suite 300, Lake Forest, IL, USA, 60045
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Assertio Holdings (FRA:DPOA) Headlines

No Headlines